EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The EPOCH study population is patients with tubo-ovarian carcinosarcoma or uterine carcinosarcoma with evidence of recurrence or progression. The study aims to determine the activity of eribulin as a single agent and the combination of eribulin and pembrolizumab as measured by clinical benefit rate (CBR) at 12 weeks. Additionally, the study aims to establish whether high mobility group A2 (HMGA2) protein expression is a good functional biomarker to predict response to eribulin and pembrolizumab.
Epistemonikos ID: f5708a6c9d309706dfaa614d5a7e1b6c912eabf4
First added on: May 14, 2024